beta2-adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart

Circulation. 1999 May 11;99(18):2458-65. doi: 10.1161/01.cir.99.18.2458.

Abstract

Background: Recent studies of beta-adrenergic receptor (beta-AR) subtype signaling in in vitro preparations have raised doubts as to whether the cAMP/protein kinase A (PKA) signaling is activated in the same manner in response to beta2-AR versus beta1-AR stimulation.

Methods and results: The present study compared, in the intact dog, the magnitude and characteristics of chronotropic, inotropic, and lusitropic effects of cAMP accumulation, PKA activation, and PKA-dependent phosphorylation of key effector proteins in response to beta-AR subtype stimulation. In addition, many of these parameters and L-type Ca2+ current (ICa) were also measured in single canine ventricular myocytes. The results indicate that although the cAMP/PKA-dependent phosphorylation cascade activated by beta1-AR stimulation could explain the resultant modulation of cardiac function, substantial beta2-AR-mediated chronotropic, inotropic, and lusitropic responses occurred in the absence of PKA activation and phosphorylation of nonsarcolemmal proteins, including phospholamban, troponin I, C protein, and glycogen phosphorylase kinase. However, in single canine myocytes, we found that beta2-AR-stimulated increases in both ICa and contraction were abolished by PKA inhibition. Thus, the beta2-AR-directed cAMP/PKA signaling modulates sarcolemmal L-type Ca2+ channels but does not regulate PKA-dependent phosphorylation of cytoplasmic proteins.

Conclusions: These results indicate that the dissociation of beta2-AR signaling from cAMP regulatory systems is only apparent and that beta2-AR-stimulated cAMP/PKA signaling is uncoupled from phosphorylation of nonsarcolemmal regulatory proteins involved in excitation-contraction coupling.

Publication types

  • Comparative Study

MeSH terms

  • Actin Cytoskeleton / metabolism
  • Adrenergic Agents / pharmacology
  • Animals
  • Calcium-Binding Proteins / metabolism
  • Cardiotonic Agents / pharmacology
  • Cyclic AMP / analogs & derivatives
  • Cyclic AMP / pharmacology
  • Cyclic AMP / physiology*
  • Cyclic AMP-Dependent Protein Kinases / physiology
  • Dogs
  • Heart / drug effects*
  • Imidazoles / pharmacology
  • Isoquinolines / pharmacology
  • Muscle Relaxation / drug effects
  • Myocardial Contraction / drug effects*
  • Myocardium / metabolism*
  • Norepinephrine / pharmacology
  • Phosphorylase Kinase / metabolism
  • Phosphorylase a / metabolism
  • Phosphorylase b / metabolism
  • Phosphorylation / drug effects
  • Protein Processing, Post-Translational* / drug effects
  • Receptors, Adrenergic, beta-1 / drug effects
  • Receptors, Adrenergic, beta-1 / physiology
  • Receptors, Adrenergic, beta-2 / drug effects
  • Receptors, Adrenergic, beta-2 / physiology*
  • Reserpine / pharmacology
  • Sarcolemma / metabolism
  • Second Messenger Systems / drug effects
  • Second Messenger Systems / physiology*
  • Sulfonamides*
  • Thionucleotides / pharmacology
  • Troponin C / metabolism

Substances

  • Adrenergic Agents
  • Calcium-Binding Proteins
  • Cardiotonic Agents
  • Imidazoles
  • Isoquinolines
  • Receptors, Adrenergic, beta-1
  • Receptors, Adrenergic, beta-2
  • Sulfonamides
  • Thionucleotides
  • Troponin C
  • phospholamban
  • adenosine-3',5'-cyclic phosphorothioate
  • Reserpine
  • CGP 20712A
  • Cyclic AMP
  • Phosphorylase a
  • Phosphorylase b
  • Phosphorylase Kinase
  • Cyclic AMP-Dependent Protein Kinases
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • Norepinephrine